DYAX – The stock was up only 5% today; I suppose the narrow margin of the panel’s endorsement and the FDA’s granting of priority review to VPHM for the same indication dampened the enthusiasm.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”